<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393701</url>
  </required_header>
  <id_info>
    <org_study_id>2020/007/HP</org_study_id>
    <nct_id>NCT04393701</nct_id>
  </id_info>
  <brief_title>A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry</brief_title>
  <acronym>LysoNeo</acronym>
  <official_title>A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include all newborns in Normandie region for 3 years (about 105,000 births)&#xD;
      for whom signed consent by one (or two) parents will be collected. Based on our previous&#xD;
      pilot study (2011) assessing MCAD and PKU using tandem mass spectrometry-based method in&#xD;
      Normandie region in which informed consents have been signed for all newborns (43,000) but we&#xD;
      are expecting a great willingness to participate to this project. Thus, we are aiming to&#xD;
      include 100,000 newborns, and the study will be continued until we reach at least this&#xD;
      target.&#xD;
&#xD;
      The primary objective is to evaluate the epidemiology of MPS1 and Pompe disease using dried&#xD;
      blood samples in the first cohort of neonates tested in France (Normandie region).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of newborns in relation to the number of cases of blotting paper collected</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of newborns with positive sample for Mucopolysaccharidosis type I</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns with positive sample for Pompe disease</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Neonatal Screening</condition>
  <condition>Lysosomal Storage Diseases</condition>
  <arm_group>
    <arm_group_label>neonates tested in Normandie, France</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All neonates will be tested in Normandie</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Additional blood sampling</intervention_name>
    <description>Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program</description>
    <arm_group_label>neonates tested in Normandie, France</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newborn in a Normandy maternity hospital&#xD;
&#xD;
          -  Newborn participating in the National Neonatal Screening Program&#xD;
&#xD;
          -  Holder(s) of parental authority having read and understood the information letter and&#xD;
             signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no criteria for non-inclusion in this study. Participation in the study, such as&#xD;
        participation in the National Neonatal Screening Program, is not mandatory.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soumeya BEKRI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soumeya BEKRI, Pr</last_name>
    <phone>+3323288</phone>
    <phone_ext>8990</phone_ext>
    <email>soumeya.bekri@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David GUENET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soumeya BEKRI</last_name>
      <phone>+3323288</phone>
      <phone_ext>8990</phone_ext>
      <email>soumeya.bekri@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

